Media

ONCLIVE: Despite the high prevalence of KRAS mutations in pancreatic cancers, a limited number of cases harbor an actionable point mutation. Unlike other tumors where variants in KRAS, such as G12C, are more prominent, explorations into the more common subtypes in pancreatic cancer have begun to provide more guidance for therapeutic development as significant differences in survival outcomes come to light.

Nature Cancer, Mota, et. al.

GENETIC ENGINEERING BIOTECHNOLOGY NEWS: The use of engineered T cells to destroy cancer cells has been successful in treating some types of cancer, such as leukemia and lymphoma. However, adoptive cell therapy using chimeric antigen receptor (CAR) T cells hasn’t worked as well for solid tumors.

Peter DeMuth, PhD, Chief Scientific Officer, Elicio Therapeutics
Koch Institute Symposia: Cancer Vaccines
June 23, 2023

THE DAILY MAIL: An off-the-shelf cancer vaccine could help prevent relapse in patients with two of the deadliest and fastest-rising cancers in the world. The shot is designed for patients whose cancers are caused by the KRAS mutation, which accounts for up to nine in 10 cases of the disease.

THE PHARMA LETTER: Along with the big pharma players showing off the potential of their cancer drugs at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), biotech companies have been making their presence felt, too.

CLINICAL TRIALS ARENA: ELI-002 2P was well-tolerated with no dose limiting toxicity or cytokine release syndrome across five cohorts.

GLOBES: Elicio Therapeutics reports positive interim results from a Phase 1 trial at risk of relapse after surgery or chemotherapy.

BIOTECH TV: Anirban Maitra and Shubham Pant from MD Anderson tell us what targets and approaches look promising in pancreatic cancer.

O’Reilly EM, Wainberg ZA, Weekes CD, et al.
Presented at the American Society of Clinical Oncology Annual Meeting
June 2-6, 2023
Chicago, IL